ELI LILLY AND COMPANY Income (Loss) from Continuing Operations, Per Diluted Share
ELI LILLY AND COMPANY (LLY) reported Income (Loss) from Continuing Operations, Per Diluted Share of $6.12 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2022-02-23
- ELI LILLY AND COMPANY income (loss) from continuing operations, per diluted share for the quarter ending 2020-09-30 was $1.33, a 2.92% decline year-over-year.
- ELI LILLY AND COMPANY income (loss) from continuing operations, per diluted share for the quarter ending 2020-06-30 was $1.55, a 7.64% increase year-over-year.
- ELI LILLY AND COMPANY income (loss) from continuing operations, per diluted share for the quarter ending 2020-03-31 was $1.60, a 180.70% increase year-over-year.
- ELI LILLY AND COMPANY income (loss) from continuing operations, per diluted share for the quarter ending 2019-12-31 was $1.64, a 49.09% increase year-over-year.
- ELI LILLY AND COMPANY income (loss) from continuing operations, per diluted share for fiscal 2021 was $6.12, a 9.87% decline from fiscal 2020.
- ELI LILLY AND COMPANY income (loss) from continuing operations, per diluted share for fiscal 2020 was $6.79, a 36.90% increase from fiscal 2019.
- ELI LILLY AND COMPANY income (loss) from continuing operations, per diluted share for fiscal 2019 was $4.96, a 62.62% increase from fiscal 2018.
- ELI LILLY AND COMPANY income (loss) from continuing operations, per diluted share for fiscal 2018 was $3.05.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2021-12-31 | $6.12 10-K · filed 2022-02-23 | |||
| 2020-12-31 | $6.79 10-K · filed 2022-02-23 | |||
| 2020-09-30 | $1.33 10-Q · filed 2020-10-28 | $4.47 10-Q · filed 2020-10-28 | ||
| 2020-06-30 | $1.55 10-Q · filed 2020-07-31 | $3.15 10-Q · filed 2020-07-31 | ||
| 2020-03-31 | $1.60 10-Q · filed 2020-05-01 | |||
| 2019-12-31 | $1.64 10-K · filed 2020-02-19 | $4.96 10-K · filed 2022-02-23 | ||
| 2019-09-30 | $1.37 10-Q · filed 2020-10-28 | $3.33 10-Q · filed 2020-10-28 | ||
| 2019-06-30 | $1.44 10-Q · filed 2020-07-31 | $1.98 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $0.57 10-Q · filed 2020-05-01 | |||
| 2018-12-31 | $1.10 10-K · filed 2020-02-19 | $3.05 10-K · filed 2021-02-17 | ||
| 2018-09-30 | $1.07 10-K · filed 2020-02-19 | $1.96 10-Q · filed 2019-10-25 | ||
| 2018-06-30 | -$0.22 10-K · filed 2020-02-19 | $0.90 10-Q · filed 2019-08-02 | ||
| 2018-03-31 | $1.11 10-K · filed 2020-02-19 | |||
| 2017-12-31 | -$1.48 8-K · filed 2019-10-24 | -$0.08 10-K · filed 2020-02-19 | ||
| 2017-09-30 | $0.52 8-K · filed 2019-10-24 | |||
| 2017-06-30 | $0.95 8-K · filed 2019-10-24 | |||
| 2017-03-31 | -$0.08 8-K · filed 2019-10-24 | |||
| 2016-12-31 | $2.57 8-K · filed 2019-10-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |